No products in the cart.
Unsupervised online yoga transiently improves symptoms in patients with knee osteoarthritis
1. Compared to a control group, patients with knee osteoarthritis who engaged in online yoga had improvements in pain and ...
Tag: rheumatology
Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases
1. An increased incidence of new cardiovascular disease was seen in individuals with autoimmune disease compared to those without. 2. ...
Litifilimab improves symptom burden for patients with systemic lupus erythematosus
1. Litifilimab was associated with a reduction in the number of swollen and tender joints in systemic lupus erythematosus (SLE) ...
Olokizumab is noninferior to adalimumab for the treatment of rheumatoid arthritis
1. Olokizumab was superior to placebo in improving rheumatoid arthritis (RA) symptoms. 2. Olokizumab was also noninferior to adalimumab in ...
Upadacitinib is safe and effective for treatment of non-radiographic axial spondyloarthritis
1. Significantly more patients in the upadacitinib group achieved ASAS40 response at week 14 compared to the placebo group. 2. ...
Litifilimab associated with reduced disease severity in patients with cutaneous lupus erythematosus
1. Litifilimab significantly decreased cutaneous lupus erythematosus (CLE) disease area and severity index scale (CLASI-A) after 16 weeks of treatment. ...
Methotrexate reduces functional burden of disease in patients with arthralgia at-risk of developing rheumatoid arthritis
1. Compared to placebo, methotrexate did not significantly reduce the risk of the development of clinical arthritis in at-risk patients. ...
ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity
1. Patients with the ACKR1 variant (CC genotype) had an elevated risk of azathioprine discontinuation attributed to hematopoietic toxicity. 2. ...
Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse ...
Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease
1. The risankizumab group showed greater clinical remission and endoscopic response rates compared to placebo across the ADVANCE and MOTIVATE ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.